Showing 261-270 of 10191 results for "".
Topical Steroid Addiction in Dermatology Today
https://practicaldermatology.com/topics/atopic-dermatitis/topical-steroid-addiction-in-dermatology-today/23140/A veteran physician shares his thoughts on the problem of topical steroid misuse.Adopting a Newly FDA-Approved Treatment for Raised Seborrheic Keratoses
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/adopting-a-newly-fda-approved-treatment-for-raised-seborrheic-keratoses/20382/Although SKs are benign and often increase with age, patients can still be bothered by them. There's a new treatment option.Successful MedSpas Focus on Every Touch Point
https://practicaldermatology.com/topics/practice-management/successful-medspas-focus-on-every-touch-point/21508/Meeting critical touch points of the medical spa experience help to positively influence patients, from viewing the spa website to checkout.Dermwire TV Extra: The Global Access to Skin Health Observatory
https://practicaldermatology.com/series/dermwire-tv/global-access-skin-health-observatory/29873/Esther Freeman, MD, PhD, Director of Global Health Dermatology at Massachusetts General Hospital and Harvard Medical School, and Vice Chair of the International Foundation of Dermatology with the International League of Dermatological Societies (ILDS), talks with Practical Dermatology about her workDermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin
https://practicaldermatology.com/topics/psoriasis/dermwiretv-clinical-support-tech-data-dupixent-stelara-updates-rihanna-launches-fenty-skin/19835/A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is Fast Tracked by the FDA for the potentiaAntibiotics and Cosmetic Trends; Seysara Launches
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-antibiotics-and-cosmetics-trends-seysara-launches/19532/Dermatologists are prescribing fewer antibiotics to manage acne and rosacea. But, the use of antibiotics after surgical procedures is on the rise. More than one third of American adults are considering a cosmetic treatment in 2019, results of a RealSelf survey show. Seysara (sarecycline), a novel teWhat Should Dermatology PAs Know About Training and Onboarding
https://practicaldermatology.com/series/pa-perspectives/what-should-dermatology-pas-know-about-training-and-onboarding/24395/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses what realistic expectations PAs should have while training and onboarding in a new practice. Topics include what new PAs should expect at 30, 60, and 90 daysDamn The Torpedoes…Full Speed Backwards
https://practicaldermatology.com/columns/editors-message/damn-the-torpedoesfull-speed-backwards/24207/At the Battle of Mobile Bay…warned of mines (called torpedoes) in the water ahead…Farragut said, “Damn the torpedoes! Captain Drayton, go ahead! Jouett, full speed!”DermWireTV: Arcutis Survey on PsO Impact; Tinted Sunscreen Update; Cosmetic Interventions and Illness; Dr. Seemal Desai Elected
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-arcutis-survey-on-pso-impact-tinted-sunscreen-update-cosmetic-interventions-and-illness-dr-seema-desai-elected/20089/Arcutis Biotherapeutics' survey finds Individuals with psoriasis who use topical treatments want more effective and simpler interventions. Intertriginous disease poses particular challenges. Increased availability of tinted sunscreens could increase the use of SPF among individuals with darker skinScientifically Speaking: Sunscreen Update from Terri Michele, MD of the FDA CDER
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-sunscreen-update-from-terri-michele-md-of-the-fda-cder/19853/What is the latest on sunscreen labeling? What are implications of recent serology studies? And could new screening agents come to the US market? Host Joel L. Cohen, MD talks to Terri Michele, MD, Director of the Office of Nonprescription Drugs in FDA CDER about these and other hot topics in sun pro